Competition Law, Health Data Network Effects and Antitrust

1. Introduction

Health data network effects arise when the competitive value of a healthcare platform, database, digital-health service, electronic-health-record system, health-insurance platform, diagnostic network, or AI-health ecosystem increases as it obtains access to more patients, providers, medical records, prescriptions, claims, diagnostic results, wearable-device information and other health-related data.

The relationship can be represented as:

More users → More health data → Better analytics/AI → Better services → More users → More data

This creates a potentially powerful data-driven feedback loop.

Health data is particularly important because it can include:

electronic health records;

diagnoses;

prescriptions;

laboratory results;

genomic information;

medical images;

insurance claims;

hospital utilisation;

treatment histories;

wearable-device information;

reproductive-health information;

pharmaceutical purchasing information; and

health-related behavioural data.

From a competition-law perspective, the important question is not simply whether a company possesses large quantities of health data. The issue is whether control over health data creates or strengthens market power and whether that power is used in an exclusionary or exploitative manner.

2. What Are Health Data Network Effects?

A traditional network effect occurs when the value of a product increases as more users join the network.

Health-data ecosystems can create a more complicated data network effect.

For example:

More hospitals → more patient records → better predictive analytics → better clinical tools → more hospitals → more records.

Similarly:

More patients → more health information → better personalised services → more patients.

Unlike ordinary social-media data, health data may possess several characteristics that increase its strategic significance:

high informational value;

longitudinal character;

difficulty of replication;

high switching costs;

interoperability dependence;

privacy constraints;

regulatory restrictions on access and transfer;

potential value for AI development.

3. The Competition-Law Problem

Health data can become a competition concern in several different ways.

First

A dominant healthcare platform may accumulate a large proprietary dataset.

Second

That dataset may improve the platform's products.

Third

Improved products attract additional users.

Fourth

Additional users generate additional data.

Fifth

The resulting data advantage makes entry increasingly difficult.

This creates a data-based competitive feedback loop.

The competition concern becomes stronger when rivals cannot realistically reproduce the same dataset.

4. Data as a Competitive Asset

Competition law traditionally focuses on:

price;

output;

quality;

innovation; and

market access.

In digital healthcare, data itself may be an important competitive parameter.

For example, two competing AI diagnostic systems might have similar algorithms, but one company may possess access to millions of high-quality longitudinal patient records.

The dataset could improve:

disease prediction;

diagnostic accuracy;

drug discovery;

patient segmentation;

risk assessment;

personalised treatment;

clinical decision support.

Thus:

Data → AI performance → consumer adoption → additional data

can reinforce market power.

5. Relevant Market Definition

A health-data competition case may involve several potentially relevant markets.

For example:

Market 1

Electronic health-record software.

Market 2

Health-data interoperability services.

Market 3

Digital healthcare platforms.

Market 4

Electronic prescribing.

Market 5

Health-insurance data analytics.

Market 6

AI diagnostic services.

Market 7

Healthcare advertising or health-related digital services.

Market 8

Data-access or data-processing services.

The same company could have different levels of market power across these markets.

Therefore, authorities should avoid automatically treating "health data" as one single market.

6. Data Network Effects and Market Power

Health-data network effects can contribute to market power through several mechanisms.

A. Scale

More records can produce better statistical and AI models.

B. Scope

A platform with information from multiple healthcare services may obtain a more comprehensive view of users.

C. Historical depth

Longitudinal records can be more valuable than isolated data points.

D. Network density

A platform connected to many hospitals, physicians and laboratories can become more useful to each participant.

E. Switching costs

Moving records between systems may be technically or practically difficult.

F. Learning effects

More data can continuously improve algorithms.

7. Data Lock-In

A major competition concern is health-data lock-in.

Suppose a hospital has used one EHR provider for ten years.

The system contains:

patient histories;

laboratory information;

prescriptions;

medical images;

billing records;

clinical notes.

Moving to another system may be expensive and technically difficult.

This can create:

Data lock-in → switching costs → reduced competitive pressure

The incumbent may consequently retain customers even if competing systems offer superior products.

8. Interoperability

Interoperability is therefore one of the most important competition issues.

A healthcare platform may control an important technical interface through which hospitals or patients access their data.

If interoperability is restricted, competitors may be unable to provide comparable services.

Potential conduct includes:

refusing API access;

technically degrading interoperability;

imposing discriminatory access conditions;

charging excessive access fees;

delaying data portability;

restricting third-party applications.

Such conduct can become particularly important where the platform is dominant and the data infrastructure is difficult to replicate.

9. Refusal to Supply Health Data

A refusal to provide data may potentially raise essential-facilities or refusal-to-deal questions, but dominance alone does not create an unlimited obligation to share proprietary information.

Competition authorities generally need to examine questions such as:

Is the undertaking dominant?

Is the requested data genuinely indispensable?

Can competitors obtain equivalent information elsewhere?

Is duplication economically or technically feasible?

Would refusal eliminate effective competition?

Is there a legitimate justification?

Would compulsory access undermine investment incentives?

Health data introduces an additional complication:

Competition law cannot simply require unrestricted disclosure of sensitive medical information.

Privacy, cybersecurity, consent and medical confidentiality must also be respected.

10. Privacy as a Competition Parameter

Privacy can sometimes constitute a non-price dimension of competition.

Consumers may prefer:

Service A because it collects less health information.

If a dominant platform substantially reduces privacy protections without competitive constraints, the resulting deterioration in quality may potentially be relevant to competition analysis.

This idea has become particularly important in digital-platform cases.

11. Combining Health Data Across Services

One of the most significant concerns arises where a company combines health data with data obtained from unrelated services.

For example:

Health app + search engine + advertising platform + wearable device + insurance platform

could generate an exceptionally comprehensive dataset.

Combining datasets may create:

stronger profiling;

greater targeting capabilities;

improved prediction;

increased barriers to entry.

But data combination may also generate legitimate efficiencies.

Therefore, competition analysis must distinguish:

efficient data integration

from

anticompetitive leveraging or foreclosure.

12. Self-Preferencing in Health Data Ecosystems

Suppose a platform operates:

an EHR system;

a health-data marketplace;

an AI diagnostic product.

The platform could potentially use information obtained from the first two services to improve its own AI product while restricting competing AI providers' access to equivalent information.

This can produce a form of:

data-based self-preferencing.

The Google Shopping jurisprudence provides an important general analogy for analysing this type of platform behaviour.

13. Exclusive Data Arrangements

Hospitals or laboratories might enter exclusive arrangements with a particular technology company.

For example:

Hospital network agrees to provide certain datasets exclusively to Platform A.

Exclusivity can have substantial effects where:

the dataset is particularly valuable;

alternative sources are limited;

the arrangement covers a substantial proportion of the market;

the agreement is long-term;

competitors cannot reproduce the dataset.

The analysis must nevertheless consider legitimate reasons such as:

cybersecurity;

standardisation;

research costs;

data quality;

patient consent;

regulatory compliance.

14. Data Tying

A dominant healthcare platform could potentially condition access to one service upon acceptance of another.

For example:

Access to a health-record system is conditioned on using the platform's analytics service.

Or:

Access to a healthcare marketplace is conditioned on using the platform's payment or data-processing service.

Such conduct could raise tying or bundling concerns where the legal requirements for an abuse are satisfied.

15. Predatory or Exclusionary Data Strategies

Competition law traditionally examines predatory pricing.

Digital healthcare raises a related question:

Can a company strategically provide a data service below cost to obtain control over a strategically important dataset?

For example, a platform might provide free healthcare software to hospitals while building a large data ecosystem.

Free products are not inherently anti-competitive.

But where free provision is combined with:

exclusionary contracts;

denial of interoperability;

tying;

data foreclosure; or

subsequent exploitation of dominance,

competition authorities may need to examine the overall strategy.

16. AI and Health Data

Artificial intelligence makes health-data competition particularly significant.

AI systems require:

training datasets;

validation datasets;

clinical records;

medical images;

genomic information;

diagnostic outcomes.

A company controlling a large healthcare dataset may therefore have a substantial advantage in developing AI systems.

This could produce:

Data → Model quality → Adoption → More data → Better model

Such feedback mechanisms can create AI-health-data concentration.

17. Case Law 1: IMS Health — Case C-418/01

Facts

IMS Health operated a system for collecting and structuring pharmaceutical sales information. Competitors sought access to its data structure.

The European Court of Justice considered when refusal to license intellectual property could constitute an abuse of dominance.

Principle

The Court established demanding conditions for converting a refusal to license into an abuse, particularly where access is indispensable for competing in a downstream market.

Relevance to Health Data

The case is important because healthcare competition frequently involves proprietary information systems.

It illustrates that:

Possession of valuable information does not automatically create a duty to share it.

For a health-data platform, the analysis would need to consider whether the data or interface is genuinely indispensable and whether refusal would eliminate effective competition.

18. Case Law 2: Google Shopping

Facts

Google operated the dominant general search engine while also providing a comparison-shopping service.

The European Commission found that Google systematically favoured its own comparison-shopping service in search results.

Competition Principle

The case demonstrates how control over a critical platform or gateway can potentially be used to advantage an affiliated service.

Health-Data Relevance

Imagine a company controlling:

Health-data platform → search/ranking system → competing health service.

If the platform systematically favoured its own healthcare products while disadvantaging competitors, Google Shopping provides an important analytical precedent.

The relevant issue would be whether the conduct produces exclusionary effects in the relevant market.

19. Case Law 3: Google Android

Facts

The European Commission examined Google's contractual arrangements involving Android, including restrictions relating to applications and competing services.

Competition Issues

The case involved:

tying;

contractual restrictions;

leveraging;

ecosystem effects;

barriers to competing services.

Health-Data Relevance

A healthcare ecosystem may similarly combine:

EHR;

health applications;

cloud services;

analytics;

payments;

AI.

If a dominant firm uses control over one layer to disadvantage competitors at another layer, the Android principles can provide useful guidance.

20. Case Law 4: United States v. Microsoft

Facts

Microsoft possessed substantial power in operating systems and was found to have engaged in exclusionary conduct involving the browser market.

Competition Issues

The case is important for:

platform power;

network effects;

entry barriers;

exclusionary agreements;

leveraging control over a platform.

Health-Data Relevance

Health-data infrastructures can function as technological platforms.

An incumbent EHR provider with extensive network connections may have the ability to make competing applications less effective by restricting interoperability or access.

The Microsoft case therefore provides a useful framework for analysing platform-based foreclosure.

21. Case Law 5: FTC v. Surescripts

This case is particularly important for health-data competition.

Facts

Surescripts operated an important electronic-prescribing network in the United States.

The FTC alleged that Surescripts maintained monopoly power through exclusionary practices, including contractual arrangements involving pharmacies and healthcare providers.

The dispute concerned competition in electronic prescribing rather than a general health-data market.

Competition Significance

The case illustrates how network effects can reinforce market power in healthcare technology.

A network becomes more valuable when:

more physicians participate;

more pharmacies participate;

more prescriptions flow through it.

This can produce:

Network participation → greater value → more participation → stronger network

Relevance

Electronic health networks therefore provide an important example of how healthcare infrastructure and network effects can create durable market power.

22. Case Law 6: FTC v. Facebook/Meta

Facts

The FTC's litigation concerning Facebook/Meta addressed alleged exclusionary conduct and the competitive significance of network effects.

Competition Principle

The case demonstrates the importance of:

network effects;

data;

user switching;

entry barriers;

platform ecosystems.

Health-Data Relevance

The same economic mechanism can occur in health platforms:

More patients → more data → better services → more patients.

The analogy must not be overstated because social-networking and healthcare markets have different characteristics.

Nevertheless, the case is useful for understanding data-enabled network effects and platform market power.

23. Case Law 7: Epic Games v. Apple

Facts

Epic challenged Apple's control over app distribution and payment arrangements.

Competition Issues

The case addressed:

platform governance;

access restrictions;

commissions;

alternative distribution;

vertical integration.

Health-Data Relevance

Healthcare applications increasingly depend upon major digital ecosystems.

If a health-data platform controls:

application access;

data interfaces;

payments;

distribution;

competition authorities may need to consider whether those rules protect legitimate security or quality objectives or instead exclude competing services.

The case is therefore a useful platform-governance analogy, rather than a health-data precedent.

24. Case Law 8: Google Android / Digital Ecosystem Jurisprudence and Health Platforms

The Google Android jurisprudence also demonstrates the importance of examining interconnected digital markets.

For a health-data ecosystem, dominance might exist at one level while competitive effects appear at another.

For example:

EHR dominance → health-data access → AI diagnostic market

or:

Wearable dominance → health data → insurance analytics

This is sometimes described as leveraging across adjacent markets.

Competition authorities must therefore examine the ecosystem without assuming that every adjacent market automatically forms part of the same relevant market.

25. Case Law 9: WhatsApp / Facebook Data-Sharing Proceedings in India

The Indian competition proceedings concerning WhatsApp's privacy policy are particularly relevant to the relationship between data, privacy and competition.

The Competition Commission of India examined concerns relating to WhatsApp's data-sharing arrangements with Facebook/Meta and the possibility that WhatsApp's position could be used to strengthen Facebook's position in another market.

Importance

The proceedings demonstrate that data practices can have a competition dimension where a powerful digital platform controls access to large amounts of user information.

Health-Data Relevance

The principle becomes even more significant for healthcare.

Health information is substantially more sensitive than ordinary consumer data.

A dominant health platform's ability to combine health information with data from other services could therefore affect:

privacy;

service quality;

market entry;

targeted advertising;

AI development;

competitive advantages.

The WhatsApp proceedings consequently provide an important Indian framework for understanding data-related competition concerns, even though they were not specifically about medical data.

26. Case-Law Matrix

27. Health Data as an Entry Barrier

A crucial question is whether a large dataset is replicable.

Suppose a new entrant needs:

10 million longitudinal patient records

to compete effectively.

If the incumbent already possesses these records and competitors cannot legally or practically acquire comparable information, the dataset may constitute an important barrier to entry.

But data can be less significant where:

equivalent datasets are widely available;

interoperability enables portability;

consumers can easily switch;

datasets become obsolete quickly;

competitors can generate equivalent information.

Therefore:

Data volume alone does not establish market power.

The quality, uniqueness, accessibility, replicability and competitive relevance of the data matter.

28. Data Portability

Data portability can reduce lock-in.

If patients can easily transfer:

medical records;

prescriptions;

diagnostic results;

wearable information;

between competing platforms, switching becomes easier.

This can increase competitive pressure.

From an antitrust perspective:

Portability → lower switching costs → greater contestability

However, portability mechanisms must also protect:

patient confidentiality;

security;

authentication;

consent;

data integrity.

29. Interoperability as a Competition Remedy

Where a dominant health-data platform has restricted interoperability, remedies could potentially include:

API access;

standardised data formats;

data portability;

non-discriminatory access;

technical interoperability;

independent auditing;

restrictions on discriminatory interface design.

Such remedies must be carefully designed because health systems have legitimate security and safety requirements.

30. Merger Control and Health Data

Health-data concentration can also arise through mergers.

Examples include:

EHR company + health analytics company

Wearable company + healthcare platform

Pharmacy platform + health-data company

Insurer + digital health platform

AI healthcare company + diagnostic database

The merger analysis may need to examine:

existing competition;

potential competition;

data assets;

network effects;

interoperability;

innovation;

privacy;

foreclosure opportunities.

A transaction that appears small in traditional revenue terms may nevertheless have strategic significance if it combines an important dataset with a rapidly developing technology.

31. Data Combination and Conglomerate Effects

Suppose one company controls:

health search;

wearable devices;

EHR software;

insurance analytics;

pharmacy services.

Combining the resulting information could create a substantial ecosystem advantage.

Potential effects include:

Efficiency

Better health recommendations and improved diagnosis.

Competition concern

Competitors cannot obtain equivalent information.

Consumer concern

Users face increased dependence on one ecosystem.

The competition analysis should therefore assess both efficiency benefits and exclusionary effects.

32. Health-Data Cartels

Health data can also facilitate horizontal coordination.

Competing hospitals, insurers, pharmacies or laboratories could potentially exchange:

prices;

treatment costs;

capacity information;

reimbursement rates;

patient demand forecasts.

Algorithms could then process the information automatically.

If competitors coordinate competitively sensitive information, traditional cartel principles can apply.

The existence of sophisticated technology does not make an otherwise unlawful agreement lawful.

33. Algorithmic Coordination

Suppose several health-insurance platforms use the same algorithm to determine prices.

The important question is:

Are competitors independently using similar technology, or is there an agreement or coordinated mechanism connecting them?

Independent algorithmic decision-making is not automatically a cartel.

But intentional coordination facilitated by algorithms can potentially fall within established competition-law rules.

34. Privacy and Competition Should Not Be Treated as Identical

Privacy law and competition law address different questions.

Privacy law asks:

Was personal information collected, processed or transferred lawfully?

Competition law asks:

Does the conduct harm the competitive process?

The same conduct may potentially raise both sets of concerns, but a privacy violation is not automatically an antitrust violation.

Conversely, a competition problem may exist even where data processing complies with privacy law.

35. Indian Competition-Law Framework

For India, the principal provisions include:

Section 3

Addresses anti-competitive agreements.

Relevant examples include:

data-sharing arrangements;

exclusionary agreements;

coordinated pricing;

exclusive supply arrangements.

Section 4

Addresses abuse of dominant position.

Potential concerns include:

denial of market access;

discriminatory conditions;

tying;

leveraging;

exclusionary interoperability practices.

Sections 5 and 6

Govern merger and combination control.

Health-data acquisitions can therefore become relevant where they materially affect competition.

36. Key Antitrust Questions for Health Data

Competition authorities should ask:

Who controls the data?

Is the data commercially important?

Is the dataset unique?

Can competitors replicate it?

Can consumers switch providers?

Is interoperability available?

Does the platform control an essential gateway?

Does the platform compete with businesses using its data infrastructure?

Does it self-preference its own services?

Are there exclusive data agreements?

Does the platform combine data across markets?

Does the conduct reduce innovation?

Does it deteriorate privacy or quality as a non-price competitive parameter?

Are there legitimate security or regulatory justifications?

37. Overall Competition-Law Model

The interaction can be summarised as:

Data Accumulation
↓
Network Effects
↓
Improved Products / AI
↓
More Users and Providers
↓
More Data
↓
Higher Switching Costs
↓
Entry Barriers
↓
Potential Market Power

The antitrust problem arises where this natural feedback mechanism is reinforced through exclusionary conduct.

38. Conclusion

Health-data markets represent an important new frontier for competition law because data, network effects, interoperability, artificial intelligence and healthcare infrastructure can reinforce each other.

The principal antitrust concerns are:

health-data concentration;

data-driven network effects;

EHR lock-in;

refusal of interoperability;

discriminatory API access;

exclusive data agreements;

self-preferencing;

data-based tying;

leveraging;

privacy degradation as a potential non-price competitive parameter;

algorithmic coordination;

AI-data feedback loops;

data-driven merger concerns; and

foreclosure of healthcare innovation.

The most directly useful authorities include IMS Health, FTC v Surescripts, Google Shopping, Google Android, United States v Microsoft, FTC v Facebook/Meta, Epic Games v Apple, and the WhatsApp/Facebook competition proceedings in India.

The central principle is that health data should not automatically be treated as an antitrust asset merely because it is valuable. The critical question is whether control over data creates durable market power or enables conduct that restricts effective competition, particularly through network effects, interoperability restrictions, exclusionary agreements, self-preferencing or leveraging across healthcare markets.